Wedbush Issues Pessimistic Estimate for Passage Bio Earnings

Passage Bio, Inc. (NASDAQ:PASG) – Research analysts at Wedbush decreased their Q3 2025 earnings per share (EPS) estimates for shares of Passage Bio in a research report issued on Tuesday, May 13th. Wedbush analyst Y. Zhong now forecasts that the company will earn ($0.21) per share for the quarter, down from their prior forecast of ($0.17). The consensus estimate for Passage Bio’s current full-year earnings is ($1.03) per share. Wedbush also issued estimates for Passage Bio’s Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.91) EPS, FY2026 earnings at ($0.49) EPS, FY2027 earnings at ($0.38) EPS, FY2028 earnings at ($0.36) EPS and FY2029 earnings at ($0.36) EPS.

Passage Bio (NASDAQ:PASG) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01).

Separately, Chardan Capital dropped their price objective on Passage Bio from $7.00 to $6.00 and set a “buy” rating for the company in a report on Tuesday, March 4th.

Passage Bio Stock Up 1.5%

Shares of Passage Bio stock opened at $0.30 on Friday. Passage Bio has a fifty-two week low of $0.26 and a fifty-two week high of $1.38. The firm has a market cap of $18.77 million, a PE ratio of -0.26 and a beta of 1.68. The business’s fifty day moving average is $0.37 and its two-hundred day moving average is $0.53.

Insider Transactions at Passage Bio

In related news, major shareholder Orbimed Advisors Llc sold 78,049 shares of the stock in a transaction on Tuesday, April 22nd. The stock was sold at an average price of $0.34, for a total value of $26,536.66. Following the completion of the sale, the insider now directly owns 6,807,523 shares in the company, valued at approximately $2,314,557.82. This represents a 1.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 233,660 shares of company stock worth $77,723 in the last ninety days. Insiders own 5.00% of the company’s stock.

Institutional Trading of Passage Bio

Several large investors have recently added to or reduced their stakes in PASG. Simplex Trading LLC increased its holdings in Passage Bio by 9,311.0% in the 1st quarter. Simplex Trading LLC now owns 82,346 shares of the company’s stock valued at $29,000 after purchasing an additional 81,471 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Passage Bio by 983.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 54,479 shares of the company’s stock valued at $31,000 after purchasing an additional 49,449 shares in the last quarter. Northern Trust Corp increased its holdings in Passage Bio by 55.1% in the 4th quarter. Northern Trust Corp now owns 62,476 shares of the company’s stock valued at $35,000 after purchasing an additional 22,195 shares in the last quarter. Squarepoint Ops LLC increased its holdings in Passage Bio by 129.5% in the 4th quarter. Squarepoint Ops LLC now owns 64,099 shares of the company’s stock valued at $36,000 after purchasing an additional 36,172 shares in the last quarter. Finally, Jane Street Group LLC increased its holdings in Passage Bio by 537.2% in the 4th quarter. Jane Street Group LLC now owns 78,190 shares of the company’s stock valued at $44,000 after purchasing an additional 65,919 shares in the last quarter. 53.48% of the stock is currently owned by institutional investors and hedge funds.

Passage Bio Company Profile

Passage Bio, Inc, a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; and PBKR03, a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease.